Cargando…
Loading, please waitCargando…
Loading, please wait2026 Clinical Comparison
Your own cells (autologous) or carefully screened donor cells (allogeneic)? A side-by-side, source-by-source guide to extraction, dose, age impact, immunogenicity, evidence, safety and cost — and how Regeneris decides which path fits each patient.
Medically reviewed · 2026-05-27 · Reviewed by Dr. Claudia Labastida · Cédula 12128801
Definitions
In regenerative medicine, the most important question after "what kind of stem cell?" is "whose cells?" The two answers — autologous and allogeneic — define almost everything else about a treatment plan, from how the cells are obtained to how they behave once they reach the target tissue. Understanding this distinction is the single most useful piece of vocabulary a patient can carry into a regenerative consultation.
Autologous stem cell therapy uses cells harvested from the same person who receives them. The most common sources are bone marrow aspirate concentrate (BMAC) from the iliac crest, adipose (fat) tissue from a mini-liposuction, and peripheral blood after pharmacological mobilization. Cells are usually processed in a closed-system device the same day and re-administered in the same clinical session. Because the cells share the patient's exact genetic and immunologic profile, there is no risk of immune rejection — the recognition system simply treats them as self.
Allogeneic stem cell therapy uses cells obtained from a healthy, screened third-party donor. The dominant clinical source is the umbilical cord — Wharton's jelly, umbilical cord blood, and amniotic-derived tissue collected after consented, full-term, scheduled C-section births from rigorously screened mothers. Donor cells are expanded in a licensed cell bank to therapeutic dose, characterized per ISCT minimal criteria, frozen, and shipped to the treating clinic as a standardized, dose-controlled product. Because mesenchymal stem cells (MSCs) are immunoprivileged — they express low levels of HLA Class I and almost no HLA Class II — well-matched UC-MSC infusions have an unusually low rejection profile compared to other allogeneic cell products.
Side-by-side
The seven variables that change between autologous and allogeneic stem cell therapy — extraction procedure, age sensitivity, dose, immunogenicity, time-to-treatment, cost, and evidence base.
| Variable | Autologous (your cells) | Allogeneic (donor cells) |
|---|---|---|
| Extraction procedure | Bone marrow aspiration (iliac crest), mini-liposuction, or peripheral blood with mobilization — performed on the patient same day. | Off-the-shelf — no harvest from the patient. Donor tissue was collected previously and processed in a licensed cell bank. |
| Age impact on cell quality | Strong. MSC count and proliferative capacity decline ~10× from age 20 to age 70. Patients over 60 often yield insufficient cells from bone marrow. | None. Umbilical cord MSCs come from neonatal tissue — telomeres are intact, proliferation rates are 2–3× higher than adult-source cells. |
| Dose (typical therapeutic range) | BMAC: ~30–60 million nucleated cells per intra-articular dose; SVF: variable; rarely culture-expanded outside of trials. | UC-MSC: 50–200 million MSCs per IV infusion or 30–100 million per intra-articular dose — standardized per batch with a Certificate of Analysis. |
| Immunogenicity / rejection risk | Effectively zero. Cells share the patient's HLA profile by definition. | Very low for UC-MSCs (immune-privileged, naïve, low HLA expression); higher for adult-source allogeneic products. |
| Time to treatment | Same-day in most clinics — harvest and administration take 2–4 hours in a single visit. | Treatment can be scheduled within days. No harvest procedure or recovery from harvest is needed. |
| Typical cost (USD, COFEPRIS) | $2,500 – $6,000 per session for BMAC/SVF intra-articular; less common for systemic protocols. | $3,500 – $9,500 per UC-MSC IV infusion; $4,000 – $8,000 per intra-articular dose with documented batch. |
| Evidence base (peer-reviewed) | Strong for orthopedic intra-articular use (BMAC for knee OA — Hernigou, Centeno, Mardones); decades of safety data in hematology. | Strong for hematopoietic allo-HSCT; growing for UC-MSC in autoimmune, anti-inflammatory, and orthopedic indications — many Phase II–III trials underway. |
All figures reflect typical COFEPRIS-regulated clinic pricing in Cancún, Mexico (2026 USD). Exact cell dose, session count, and final cost depend on the protocol designed during your medical evaluation. PRP (platelet-rich plasma) is biologically distinct from MSC therapy and is not included in this comparison.
Better candidates
Autologous protocols are often the better starting point for younger patients with localized orthopedic or aesthetic conditions where the lower cell yield is offset by zero immunologic risk and a simpler regulatory footprint.
Patients in their 30s, 40s and early 50s typically have enough residual bone marrow MSC reserve to generate a clinically meaningful BMAC dose. Combined with PRP for synergy, autologous protocols can deliver real outcomes at lower cost in this group.
For localized osteoarthritis or focal cartilage injury at one or two joints, an autologous BMAC injection delivers a high concentration of growth factors and progenitor cells directly into the lesion. Total dose required is lower than for a systemic IV protocol, so harvest is feasible.
Combining bone marrow aspirate concentrate with platelet-rich plasma harnesses both progenitor cells and platelet growth factors from the same patient in one session. This is one of the most evidence-supported autologous orthopedic strategies.
Autologous protocols require a scheduled harvest day. If the condition is chronic and the patient can plan around a one-day clinic visit, autologous is logistically straightforward.
Patients with strong personal preference against donor-derived tissue, or with active autoimmune flares where reducing any external immune stimulus is desired, are reasonable candidates for an autologous-first plan.
Better candidates
Allogeneic UC-MSC protocols are often the better choice for older patients, for multi-system conditions, and for any protocol where dose, repeatability, or speed matters more than the technical purity of using the patient's own tissue.
MSC quantity and quality in bone marrow drop sharply after age 60. For many older patients an autologous harvest simply does not produce enough viable progenitor cells to reach therapeutic dose. UC-MSCs from a cell bank deliver a known, dose-controlled count from neonatal tissue regardless of patient age.
When a patient presents with overlapping degenerative-inflammatory conditions (e.g., osteoarthritis + chronic fatigue + post-COVID inflammation + autoimmune flare), a systemic IV UC-MSC protocol can address several axes simultaneously. The same coverage would require multiple autologous harvests over weeks.
Therapeutic IV protocols typically require 100–200 million MSCs per session. Reaching this dose from autologous bone marrow is impractical without weeks of culture expansion. Allogeneic UC-MSC banks deliver this dose in a single thawed bag.
UC-MSCs are particularly studied for paracrine immune modulation — secreting cytokines and extracellular vesicles that down-regulate Th1/Th17 inflammation and promote regulatory T-cell phenotypes. For autoimmune-adjacent indications this paracrine effect is often the desired mechanism, not direct engraftment.
Patients with bleeding disorders, advanced sarcopenia, severe spinal pathology, or hardware near the iliac crest may not be candidates for bone marrow aspiration. Allogeneic UC-MSC infusion removes the harvest step entirely.
Source biology
Autologous and allogeneic are categories — not protocols. Within each category, the specific cell source carries its own biology, harvest profile, and indication fit. The four sources you will most often see at a regulated Mexican clinic.
Drawn from the iliac crest under local anesthesia, BM-MSCs are typically delivered as BMAC (bone marrow aspirate concentrate) — a same-day, autologous, minimally manipulated product. Best-evidenced for orthopedic intra-articular use. Cell count and clonogenic potential decline sharply with patient age.
Obtained via mini-liposuction from abdominal or flank fat. The processed product (stromal vascular fraction, or SVF) contains a higher progenitor density per gram of tissue than bone marrow and is logistically simpler to harvest. Available as autologous in many countries; allogeneic adipose products are less common than UC-MSCs.
The dominant allogeneic source. Wharton's jelly (the gelatinous tissue inside the umbilical cord) yields young, highly proliferative MSCs with intact telomeres, strong paracrine secretome, and low immunogenicity. Always allogeneic, always from a licensed cell bank with documented donor screening and Certificate of Analysis per batch.
Exosomes are nano-sized vesicles secreted by stem cells (typically UC-MSCs) that carry the cells' bioactive cargo — growth factors, microRNAs, and signaling proteins — without containing the cells themselves. Because they are acellular, exosomes have a different regulatory profile and are used adjunctively for systemic anti-inflammatory and aesthetic protocols.
Safety profile
Both autologous and allogeneic stem cell therapies have strong safety records when sourced and administered correctly, but the risk profiles are different — and worth understanding before choosing a protocol.
What matters: The risk that genuinely matters is neither autologous-vs-allogeneic in the abstract — it is licensed-vs-unlicensed. A licensed Mexican clinic running autologous BMAC has a near-identical safety floor to a licensed clinic running allogeneic UC-MSC. An unlicensed clinic running either has a fundamentally worse risk profile. Always verify the COFEPRIS Aviso Sanitario, the treating physician's cédula profesional, and — for allogeneic protocols — the Certificate of Analysis for your specific cell batch.
Clinical decision-making
We do not have a default. Every patient receives a structured medical evaluation, and the autologous-vs-allogeneic question is answered case-by-case based on a written set of criteria.
Recent imaging, current medications, autoimmune history, oncologic history, bleeding disorders, prior orthopedic surgeries, and lifestyle context (sleep, nutrition, training load) are reviewed before a protocol is proposed.
Is the goal localized cartilage support at one joint (favors autologous intra-articular)? Multi-joint orthopedic load (consider allogeneic)? Systemic anti-inflammatory or immune modulation (favors allogeneic IV UC-MSC)?
Patients under 55 with no chronic disease are reasonable candidates for autologous BMAC. Patients over 60, or with chemotherapy/radiation history affecting marrow, are typically routed to allogeneic UC-MSC for dose reliability.
How many MSCs do we need per session, and how many sessions over what calendar? Once the dose target is set, we choose the source most capable of delivering it reproducibly.
Bleeding-disorder patients, those on anticoagulants who cannot pause therapy, patients with sarcopenia or anatomical limitations near the iliac crest, and patients with strong preference against any harvest procedure are routed toward allogeneic.
Every accepted patient receives a written treatment protocol stating the cell source, dose, route, session schedule, and the clinical reasoning behind the autologous-vs-allogeneic decision. The decision and its rationale go into the medical chart and the informed-consent document.
FAQ
The eight questions patients ask us most often when weighing autologous vs allogeneic stem cell therapy.
Autologous means your own cells, drawn from your body and re-administered the same day or after expansion. Allogeneic means donor cells, obtained from a screened third party — almost always neonatal umbilical-cord tissue in modern protocols — expanded in a licensed cell bank to a standardized dose. Both are legitimate, evidence-supported approaches; the right one depends on your age, the condition, the dose required, and your tolerance for a harvest procedure.
Both have strong safety profiles at licensed clinics. Autologous has zero immunologic rejection risk by definition, but carries small harvest-procedure risks (bleeding, soreness, rare infection at the puncture site). Allogeneic UC-MSCs come from immune-privileged neonatal tissue with low HLA expression — published rejection events are rare — and require rigorous donor screening plus a per-batch Certificate of Analysis. The real safety distinction is licensed vs unlicensed clinic, not autologous vs allogeneic.
Bone-marrow MSC count and proliferative capacity decline roughly 10-fold from age 20 to age 70. For patients over 60, an autologous bone marrow harvest often does not yield enough viable progenitor cells to reach therapeutic dose. Allogeneic UC-MSCs come from neonatal tissue — telomeres are intact, replication potential is high, and dose is standardized per bag, so the patient's age does not lower the dose delivered.
Yes — combination protocols are common. A patient with bilateral knee osteoarthritis plus systemic inflammation may receive an autologous BMAC injection into one knee for the locally concentrated cartilage support, plus an allogeneic UC-MSC IV infusion the same week for the systemic anti-inflammatory effect. The combined protocol is designed during medical evaluation and documented in writing.
Yes. Allogeneic umbilical-cord MSC therapy is permitted in Mexico under licensed protocols when sourced from a COFEPRIS-registered cell bank, administered by a physician with active cédula profesional, and delivered in a clinic with an Aviso de Funcionamiento. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 — both verifiable on the COFEPRIS portal.
Compliant Mexican cell banks follow a layered screening protocol: explicit informed consent from the donating mother, infectious-disease panel on maternal blood (HIV, HBV, HCV, HTLV, syphilis, CMV plus regional add-ons), genetic and hereditary screening, sterility and endotoxin testing of the final product, and ISCT minimal-criteria surface marker characterization (CD90+, CD73+, CD105+ ≥95%; CD34, CD45, HLA-DR <2%). Every batch ships with a Certificate of Analysis listing all results — refuse any clinic that cannot produce one.
No. Mesenchymal stem cells from umbilical cord tissue are immune-privileged — they express very low HLA Class I and almost no HLA Class II. Published clinical series do not show a requirement for systemic immunosuppression with UC-MSC infusion. This is biologically distinct from hematopoietic stem cell transplant (HSCT) for blood cancers, which uses different cell types and does require immunosuppression. Patients should still disclose all current immunomodulating medications during evaluation.
Autologous BMAC for a single intra-articular knee injection is typically the lowest-cost regulated stem cell intervention available (USD $2,500–$6,000 per session at a COFEPRIS clinic). Allogeneic UC-MSC IV protocols cost more per session ($3,500–$9,500) because the cells were previously processed and expanded in a licensed bank, but they deliver higher dose and broader systemic effect. Cost-effectiveness depends on the indication: localized orthopedic problem often favors autologous; multi-system or systemic inflammation often favors allogeneic.
Continue exploring
The full overview of stem cell therapy at Regeneris Therapy: cell sources, protocols, and how to start.
ContinueWhat MSCs are, how they work, ISCT minimal criteria, and what they can and cannot do.
ContinueDeep dive on Wharton's jelly UC-MSCs — donor screening, cell-bank standards, and clinical indications.
ContinueThe clinical service page: indications, protocol pathway, and how to begin an evaluation.
ContinueA plain-language deep dive for patients on the trade-offs between your own cells and donor cells.
ContinueStart with a 60-minute physician evaluation — virtual or in-clinic — to choose the right cell source for your case.
ContinueCédula-verified physicians and biotechnologists who design every autologous-vs-allogeneic decision.
ContinueThis page is informational and does not constitute medical advice. Regenerative medicine outcomes vary by patient, condition, cell source, and dose. Stem cell therapy is not FDA-approved for most indications discussed here, and most US insurance plans do not reimburse it. The autologous-vs-allogeneic decision should always follow an in-person evaluation with a licensed physician who can review your full medical history, current medications, imaging, and labs. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, Mexico.
Book a free 15-min call with our team.
Send your recent imaging, labs, and current medication list. Within 1–2 business days, one of our physicians will email you a written assessment of whether autologous, allogeneic, or a combined protocol is the better fit — with a transparent quote in USD if you are a candidate.